Viking Therapeutics (VKTX) announced the completion of patient enrollment in its exploratory maintenance dosing study of VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics names Neil Aubuchon as Chief Commercial Officer
- These 3 Biotech Stocks Can Triple from Current Levels, Say Five-Star Analysts – 12/19/2025
- Viking Therapeutics: External Validation and Same-Molecule Strategy De-Risk Obesity Program, Supporting Buy Rating
- H.C. Wainwright says Lilly’s topline results de-risk Viking oral VK2735 program
- Crypto Currents: Bitcoin settlement volume flips Visa